The Role of the Brain's Endocannabinoid System in Pain and Its Modulation by Stress

International Review of Neurobiology

Volumn 125, Issue , 2015, Pages 203-255

  Corcoran, Louise ^a   Roche, Michelle ^a   Finn, David P ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

2 Arachidonyl glycerol; Anandamide; Cannabinoid CB1 receptor; Descending pain pathway; Fear; Nociception

Indexed keywords

1 (2 METHYL 6 BENZOXAZOLYL) 3 (1,5 NAPHTHYRIDIN 4 YL)UREA; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 AMINOBUTYRIC ACID; ANTIINFLAMMATORY AGENT; ARVANIL; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CAPSAZEPINE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; GLUTAMIC ACID; MONOAMINE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; N OLEOYLETHANOLAMINE; NERVE GROWTH FACTOR; NEUROTRANSMITTER; OLVANIL; OPIATE; OREXIN; PARACETAMOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHOLIPASE D; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 1 ANTAGONIST;

ALLODYNIA; AMYGDALA; ANALGESIA; ANALGESIC ACTIVITY; ANTERIOR CINGULATE; COMORBIDITY; DISEASE EXACERBATION; HUMAN; HYPERALGESIA; INFRALIMBIC CORTEX; MODULATION; MOUSE; NONHUMAN; PAIN; PERIAQUEDUCTAL GRAY MATTER; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAPHE MAGNUS NUCLEUS; RAT; ROSTRAL VENTROMEDIAL MEDULLA; STRESS; STRESS INDUCED ANALGESIA; STRESS INDUCED HYPERALGESIA; ANIMAL; BRAIN; MENTAL STRESS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN; ENDOCANNABINOIDS; HUMANS; PAIN; STRESS, PSYCHOLOGICAL;

EID: 84949491311     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.irn.2015.10.003     Document Type: Chapter

References (233)

1. Aguggia M. Neurophysiology of pain. Neurological Science 2003, 24(Suppl. 2):S57-S60.
2. Aicher S.A., Hermes S.M., Whittier K.L., Hegarty D.M. Descending projections from the rostral ventromedial medulla (RVM) to trigeminal and spinal dorsal horns are morphologically and neurochemically distinct. Journal of Chemical Neuroanatomy 2012, 43(2):103-111.
3. Alexander S.P., Kendall D.A. The complications of promiscuity: Endocannabinoid action and metabolism. British Journal of Pharmacology 2007, 152(5):602-623.
4. Asmundson G.J., Katz J. Understanding the co-occurrence of anxiety disorders and chronic pain: State-of-the-art. Depression and Anxiety 2009, 26(10):888-901.
5. Azhdari Zarmehri H., Semnanian S., Fathollahi Y., Erami E., Khakpay R., Azizi H., et al. Intra-periaqueductal gray matter microinjection of orexin-A decreases formalin-induced nociceptive behaviors in adult male rats. The Journal of Pain 2012, 12(2):280-287.
6. Baek J.H., Zheng Y., Darlington C.L., Smith P.F. Cannabinoid CB2 receptor expression in the rat brainstem cochlear and vestibular nuclei. Acta Oto-Laryngologica 2008, 128(9):961-967.
7. Bandler R., Keay K.A. Columnar organization in the midbrain periaqueductal gray and the integration of emotional expression. Progress in Brain Research 1996, 107:285-300.
8. Barriere D.A., Mallet C., Blomgren A., Simonsen C., Daulhac L., Libert F., et al. Fatty acid amide hydrolase-dependent generation of antinociceptive drug metabolites acting on TRPV1 in the brain. PLoS One 2013, 8(8):e70690.
9. Basbaum A.I., Fields H.L. Endogenous pain control systems: Brainstem spinal pathways and endorphin circuitry. Annual Review of Neuroscience 1984, 7:309-338.
10. Battista N., Di Tommaso M., Bari M., Maccarrone M. The endocannabinoid system: An overview. Frontiers in Behavioral Neuroscience 2012, 6:9.
11. Beltramo M., Piomelli D. Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. Neuroreport 2000, 11(6):1231-1235.
12. Berdyshev E.V. Cannabinoid receptors and the regulation of immune response. Chemistry and Physics of Lipids 2000, 108(1-2):169-190.
13. Bisogno T., Ligresti A., Di Marzo V. The endocannabinoid signalling system: Biochemical aspects. Pharmacology Biochemistry and Behavior 2005, 81(2):224-238.
14. Blankman J.L., Cravatt B.F. Chemical probes of endocannabinoid metabolism. Pharmacological Reviews 2013, 65(2):849-871.
15. Blankman J.L., Simon G.M., Cravatt B.F. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chemistry & Biology 2007, 14(12):1347-1356.
16. Blyth F.M., March L.M., Brnabic A.J., Jorm L.R., Williamson M., Cousins M.J. Chronic pain in Australia: A prevalence study. Pain 2001, 89(2-3):127-134.
17. Bouaboula M., Poinot-Chazel C., Bourrie B., Canat X., Calandra B., Rinaldi-Carmona M., et al. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. The Biochemical Journal 1995, 312(Pt. 2):637-641.
18. Breivik H., Collett B., Ventafridda V., Cohen R., Gallacher D. Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. European Journal of Pain 2006, 10(4):287-333.
19. Brown A.J. Novel cannabinoid receptors. British Journal of Pharmacology 2007, 152(5):567-575.
20. Burke N.N., Finn D.P., Roche M. Neuroinflammatory mechanisms linking pain and depression: Pain in psychiatric disorders. Modern Trends in Pharmacopsychiatry 2015, 30:36-50.
21. Burke N.N., Hayes E., Calpin P., Kerr D.M., Moriarty O., Finn D.P., et al. Enhanced nociceptive responding in two rat models of depression is associated with alterations in monoamine levels in discrete brain regions. Neuroscience 2010, 171(4):1300-1313.
22. Butler R.K., Finn D.P. Stress-induced analgesia. Progress in Neurobiology 2009, 88(3):184-202.
23. Butler R.K., Rea K., Lang Y., Gavin A.M., Finn D.P. Endocannabinoid-mediated enhancement of fear-conditioned analgesia in rats: Opioid receptor dependency and molecular correlates. Pain 2008, 140(3):491-500.
24. Carrier E.J., Patel S., Hillard C.J. Endocannabinoids in neuroimmunology and stress. Current Drug Targets. CNS and Neurological Disorders 2005, 4(6):657-665.
25. Casey K.L., Minoshima S., Morrow T.J., Koeppe R.A. Comparison of human cerebral activation pattern during cutaneous warmth, heat pain, and deep cold pain. Journal of Neurophysiology 1996, 76(1):571-581.
26. Castane A., Celerier E., Martin M., Ledent C., Parmentier M., Maldonado R., et al. Development and expression of neuropathic pain in CB1 knockout mice. Neuropharmacology 2006, 50(1):111-122.
27. Caterina M.J., Leffler A., Malmberg A.B., Martin W.J., Trafton J., Petersen-Zeitz K.R., et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000, 288(5464):306-313.
28. Chhatwal J.P., Ressler K.J. Modulation of fear and anxiety by the endogenous cannabinoid system. CNS Spectrums 2007, 12(3):211-220.
29. Chiou L.C., Lee H.J., Ho Y.C., Chen S.P., Liao Y.Y., Ma C.H., et al. Orexins/hypocretins: Pain regulation and cellular actions. Current Pharmaceutical Design 2010, 16(28):3089-3100.
30. Concannon R.M., Okine B.N., Finn D.P., Dowd E. Differential upregulation of the cannabinoid CB(2) receptor in neurotoxic and inflammation-driven rat models of Parkinson's disease. Experimental Neurology 2015, 269:133-141.
31. Connell K., Bolton N., Olsen D., Piomelli D., Hohmann A.G. Role of the basolateral nucleus of the amygdala in endocannabinoid-mediated stress-induced analgesia. Neuroscience Letters 2006, 397(3):180-184.
32. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(16):9371-9376.
33. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996, 384(6604):83-87.
34. Cui M., Honore P., Zhong C., Gauvin D., Mikusa J., Hernandez G., et al. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists. The Journal of Neuroscience 2006, 26(37):9385-9393.
35. D'Agostino G., La Rana G., Russo R., Sasso O., Iacono A., Esposito E., et al. Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-alpha agonist, modulates carrageenan-induced paw edema in mice. The Journal of Pharmacology and Experimental Therapeutics 2007, 322(3):1137-1143.
36. D'Agostino G., La Rana G., Russo R., Sasso O., Iacono A., Esposito E., et al. Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia. European Journal of Pharmacology 2009, 613(1-3):54-59.
37. Davis K.D., Taylor S.J., Crawley A.P., Wood M.L., Mikulis D.J. Functional MRI of pain- and attention-related activations in the human cingulate cortex. Journal of Neurophysiology 1997, 77(6):3370-3380.
38. de Lecea L., Kilduff T.S., Peyron C., Gao X., Foye P.E., Danielson P.E., et al. The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity. Proceedings of the National Academy of Sciences of the United States of America 1998, 95(1):322-327.
39. De Leon M., Welcher A.A., Nahin R.H., Liu Y., Ruda M.A., Shooter E.M., et al. Fatty acid binding protein is induced in neurons of the dorsal root ganglia after peripheral nerve injury. Journal of Neuroscience Research 1996, 44(3):283-292.
40. de Novellis V., Palazzo E., Rossi F., De Petrocellis L., Petrosino S., Guida F., et al. The analgesic effect of N-arachidonoyl-serotonin, a FAAH inhibitor and TRPV1 receptor antagonist, associated with changes in rostral ventromedial medulla and locus coeruleus cell activity in rats. Neuropharmacology 2008, 55(7):1105-1113.
41. de Novellis V., Vita D., Gatta L., Luongo L., Bellini G., De Chiaro M., et al. The blockade of the transient receptor potential vanilloid type 1 and fatty acid amide hydrolase decreases symptoms and central sequelae in the medial prefrontal cortex of neuropathic rats. Molecular Pain 2011, 7:7.
42. de Wied M., Verbaten M.N. Affective pictures processing, attention, and pain tolerance. Pain 2001, 90(1-2):163-172.
43. Deliu E., Sperow M., Console-Bram L., Carter R.L., Tilley D.G., Kalamarides D.J., et al. The lysophosphatidylinositol receptor GPR55 modulates pain perception in the periaqueductal gray. Molecular Pharmacology 2015, 88(2):265-272.
44. Demuth D.G., Molleman A. Cannabinoid signalling. Life Sciences 2006, 78(6):549-563.
45. Demyttenaere K., Bruffaerts R., Lee S., Posada-Villa J., Kovess V., Angermeyer M.C., et al. Mental disorders among persons with chronic back or neck pain: Results from the World Mental Health Surveys. Pain 2007, 129(3):332-342.
46. Derbyshire S.W., Jones A.K., Gyulai F., Clark S., Townsend D., Firestone L.L. Pain processing during three levels of noxious stimulation produces differential patterns of central activity. Pain 1997, 73(3):431-445.
47. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology 1988, 34(5):605-613.
48. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258(5090):1946-1949.
49. Di Marzo V. Endocannabinoids: Synthesis and degradation. Reviews of Physiology, Biochemistry and Pharmacology 2008, 160:1-24.
50. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994, 372(6507):686-691.
51. Di Marzo V., Stella N., Zimmer A. Endocannabinoid signalling and the deteriorating brain. Nature Reviews Neuroscience 2015, 16(1):30-42.
52. Diorio D., Viau V., Meaney M.J. The role of the medial prefrontal cortex (cingulate gyrus) in the regulation of hypothalamic-pituitary-adrenal responses to stress. The Journal of Neuroscience 1993, 13(9):3839-3847.
53. Dougher M.J. Sensory decision theory analysis of the effects of anxiety and experimental instructions on pain. Journal of Abnormal Psychology 1979, 88(2):137-144.
54. Egertova M., Cravatt B.F., Elphick M.R. Comparative analysis of fatty acid amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: Evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 2003, 119(2):481-496.
55. Escobar W., Ramirez K., Avila C., Limongi R., Vanegas H., Vazquez E. Metamizol, a non-opioid analgesic, acts via endocannabinoids in the PAG-RVM axis during inflammation in rats. European Journal of Pain 2012, 16(5):676-689.
56. Fang Q., Han Z.L., Li N., Wang Z.L., He N., Wang R. Effects of neuropeptide FF system on CB(1) and CB(2) receptors mediated antinociception in mice. Neuropharmacology 2012, 62(2):855-864.
57. Fields H.L., Heinricher M.M., Mason P. Neurotransmitters in nociceptive modulatory circuits. Annual Review of Neuroscience 1991, 14:219-245.
58. Finn D.P. Endocannabinoid-mediated modulation of stress responses: Physiological and pathophysiological significance. Immunobiology 2010, 215(8):629-646.
59. Finn D.P., Beckett S.R., Richardson D., Kendall D.A., Marsden C.A., Chapman V. Evidence for differential modulation of conditioned aversion and fear-conditioned analgesia by CB1 receptors. The European Journal of Neuroscience 2004, 20(3):848-852.
60. Finn D.P., Jhaveri M.D., Beckett S.R., Roe C.H., Kendall D.A., Marsden C.A., et al. Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. Neuropharmacology 2003, 45(5):594-604.
61. Fitzgibbon M., Finn D.P., Roche M. High times for painful blues: The endocannabinoid system in pain-depression comorbidity. International Journal of Neuropsychopharmacology 2015, 10.1093/ijnp/pyv095.
62. Ford G.K., Finn D.P. Clinical correlates of stress-induced analgesia: Evidence from pharmacological studies. Pain 2008, 140(1):3-7.
63. Ford G.K., Kieran S., Dolan K., Harhen B., Finn D.P. A role for the ventral hippocampal endocannabinoid system in fear-conditioned analgesia and fear responding in the presence of nociceptive tone in rats. Pain 2011, 152(11):2495-2504.
64. Freitas R.L., Salgado-Rohner C.J., Hallak J.E., Crippa J.A., Coimbra N.C. Involvement of prelimbic medial prefrontal cortex in panic-like elaborated defensive behaviour and innate fear-induced antinociception elicited by GABAA receptor blockade in the dorsomedial and ventromedial hypothalamic nuclei: Role of the endocannabinoid CB1 receptor. The International Journal of Neuropsychopharmacology 2013, 16(8):1781-1798.
65. Fu J., Bottegoni G., Sasso O., Bertorelli R., Rocchia W., Masetti M., et al. A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nature Neuroscience 2012, 15(1):64-69.
66. Furuhashi M., Hotamisligil G.S. Fatty acid-binding proteins: Role in metabolic diseases and potential as drug targets. Nature Reviews Drug Discovery 2008, 7(6):489-503.
67. Gaskin D.J., Richard P. The economic costs of pain in the United States. The Journal of Pain 2012, 13(8):715-724.
68. Giang D.K., Cravatt B.F. Molecular characterization of human and mouse fatty acid amide hydrolases. Proceedings of the National Academy of Sciences of the United States of America 1997, 94(6):2238-2242.
69. Giordano C., Cristino L., Luongo L., Siniscalco D., Petrosino S., Piscitelli F., et al. TRPV1-dependent and -independent alterations in the limbic cortex of neuropathic mice: Impact on glial caspases and pain perception. Cerebral Cortex 2012, 22(11):2495-2518.
70. Glaser S.T., Abumrad N.A., Fatade F., Kaczocha M., Studholme K.M., Deutsch D.G. Evidence against the presence of an anandamide transporter. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(7):4269-4274.
71. Glass M., Dragunow M., Faull R.L. Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997, 77(2):299-318.
72. Goparaju S.K., Ueda N., Yamaguchi H., Yamamoto S. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Letters 1998, 422(1):69-73.
73. Greco R., Gasperi V., Maccarrone M., Tassorelli C. The endocannabinoid system and migraine. Experimental Neurology 2010, 224(1):85-91.
74. Greco R., Gasperi V., Sandrini G., Bagetta G., Nappi G., Maccarrone M., et al. Alterations of the endocannabinoid system in an animal model of migraine: Evaluation in cerebral areas of rat. Cephalalgia 2010, 30(3):296-302.
75. Gregg L.C., Jung K.M., Spradley J.M., Nyilas R., Suplita R.L., Zimmer A., et al. Activation of type 5 metabotropic glutamate receptors and diacylglycerol lipase-alpha initiates 2-arachidonoylglycerol formation and endocannabinoid-mediated analgesia. The Journal of Neuroscience 2012, 32(28):9457-9468.
76. Guindon J., Hohmann A.G. Cannabinoid CB2 receptors: A therapeutic target for the treatment of inflammatory and neuropathic pain. British Journal of Pharmacology 2008, 153(2):319-334.
77. Gulyas A.I., Cravatt B.F., Bracey M.H., Dinh T.P., Piomelli D., Boscia F., et al. Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. The European Journal of Neuroscience 2004, 20(2):441-458.
78. Hasanein P., Parviz M., Keshavarz M., Javanmardi K. CB1 receptor activation in the basolateral amygdala produces antinociception in animal models of acute and tonic nociception. Clinical and Experimental Pharmacology & Physiology 2007, 34(5-6):439-449.
79. Helmstetter F.J. The amygdala is essential for the expression of conditional hypoalgesia. Behavioral Neuroscience 1992, 106(3):518-528.
80. Helmstetter F.J., Bellgowan P.S. Lesions of the amygdala block conditional hypoalgesia on the tail flick test. Brain Research 1993, 612(1-2):253-257.
81. Helmstetter F.J., Bellgowan P.S., Poore L.H. Microinfusion of mu but not delta or kappa opioid agonists into the basolateral amygdala results in inhibition of the tail flick reflex in pentobarbital-anesthetized rats. The Journal of Pharmacology and Experimental Therapeutics 1995, 275(1):381-388.
82. Henry R.J., Kerr D.M., Finn D.P., Roche M. For whom the endocannabinoid tolls: Modulation of innate immune function and implications for psychiatric disorders. Progress in Neuropsychopharmacology and Biological Psychiatry 2015, 64:167-180.
83. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. The Journal of Neuroscience 1991, 11(2):563-583.
84. Herzberg U., Eliav E., Bennett G.J., Kopin I.J. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neuroscience Letters 1997, 221(2-3):157-160.
85. Hill M.N., Kumar S.A., Filipski S.B., Iverson M., Stuhr K.L., Keith J.M., et al. Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Molecular Psychiatry 2013, 18(10):1125-1135.
86. Hill M.N., Patel S., Carrier E.J., Rademacher D.J., Ormerod B.K., Hillard C.J., et al. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 2005, 30(3):508-515.
87. Hillard C.J., Edgemond W.S., Jarrahian A., Campbell W.B. Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. Journal of Neurochemistry 1997, 69(2):631-638.
88. Ho Y.C., Lee H.J., Tung L.W., Liao Y.Y., Fu S.Y., Teng S.F., et al. Activation of orexin 1 receptors in the periaqueductal gray of male rats leads to antinociception via retrograde endocannabinoid (2-arachidonoylglycerol)-induced disinhibition. The Journal of Neuroscience 2011, 31(41):14600-14610.
89. Hogestatt E.D., Jonsson B.A., Ermund A., Andersson D.A., Bjork H., Alexander J.P., et al. Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. The Journal of Biological Chemistry 2005, 280(36):31405-31412.
90. Hohmann A.G., Suplita R.L. Endocannabinoid mechanisms of pain modulation. The AAPS Journal 2006, 8(4):E693-E708.
91. Hohmann A.G., Suplita R.L., Bolton N.M., Neely M.H., Fegley D., Mangieri R., et al. An endocannabinoid mechanism for stress-induced analgesia. Nature 2005, 435(7045):1108-1112.
92. Hohmann A.G., Tsou K., Walker J.M. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. Journal of Neurophysiology 1999, 81(2):575-583.
93. Holt S., Comelli F., Costa B., Fowler C.J. Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: Comparison with indomethacin and possible involvement of cannabinoid receptors. British Journal of Pharmacology 2005, 146(3):467-476.
94. Hoot M.R., Sim-Selley L.J., Poklis J.L., Abdullah R.A., Scoggins K.L., Selley D.E., et al. Chronic constriction injury reduces cannabinoid receptor 1 activity in the rostral anterior cingulate cortex of mice. Brain Research 2010, 1339:18-25.
95. Howlett A.C. Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Molecular Pharmacology 1985, 27(4):429-436.
96. Howlett A.C., Mukhopadhyay S. Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chemistry and Physics of Lipids 2000, 108(1-2):53-70.
97. Howlett A.C., Mukhopadhyay S., Shim J.Y., Welsh W.J. Signal transduction of eicosanoid CB1 receptor ligands. Life Sciences 1999, 65(6-7):617-625.
98. Jayamanne A., Greenwood R., Mitchell V.A., Aslan S., Piomelli D., Vaughan C.W. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. British Journal of Pharmacology 2006, 147(3):281-288.
99. Jennings E.M., Okine B.N., Olango W.M., Roche M., Finn D.P. Repeated forced swim stress differentially affects formalin-evoked nociceptive behaviour and the endocannabinoid system in stress normo-responsive and stress hyper-responsive rat strains. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2015, 64:181-189.
100. Jennings E.M., Okine B.N., Roche M., Finn D.P. Stress-induced hyperalgesia. Progress in Neurobiology 2014, 121:1-18.
101. Jhaveri M.D., Elmes S.J., Richardson D., Barrett D.A., Kendall D.A., Mason R., et al. Evidence for a novel functional role of cannabinoid CB(2) receptors in the thalamus of neuropathic rats. The European Journal of Neuroscience 2008, 27(7):1722-1730.
102. Ji G., Neugebauer V. CB1 augments mGluR5 function in medial prefrontal cortical neurons to inhibit amygdala hyperactivity in an arthritis pain model. The European Journal of Neuroscience 2014, 39(3):455-466.
103. Ji G., Sun H., Fu Y., Li Z., Pais-Vieira M., Galhardo V., et al. Cognitive impairment in pain through amygdala-driven prefrontal cortical deactivation. The Journal of Neuroscience 2010, 30(15):5451-5464.
104. Kaczocha M., Glaser S.T., Deutsch D.G. Identification of intracellular carriers for the endocannabinoid anandamide. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(15):6375-6380.
105. Kaczocha M., Hermann A., Glaser S.T., Bojesen I.N., Deutsch D.G. Anandamide uptake is consistent with rate-limited diffusion and is regulated by the degree of its hydrolysis by fatty acid amide hydrolase. The Journal of Biological Chemistry 2006, 281(14):9066-9075.
106. Kaczocha M., Vivieca S., Sun J., Glaser S.T., Deutsch D.G. Fatty acid-binding proteins transport N-acylethanolamines to nuclear receptors and are targets of endocannabinoid transport inhibitors. The Journal of Biological Chemistry 2012, 287(5):3415-3424.
107. Katona I., Rancz E.A., Acsady L., Ledent C., Mackie K., Hajos N., et al. Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. The Journal of Neuroscience 2001, 21(23):9506-9518.
108. Knerlich-Lukoschus F., Noack M., von der Ropp-Brenner B., Lucius R., Mehdorn H.M., Held-Feindt J. Spinal cord injuries induce changes in CB1 cannabinoid receptor and C-C chemokine expression in brain areas underlying circuitry of chronic pain conditions. Journal of Neurotrauma 2011, 28(4):619-634.
109. Kulkarni B., Bentley D.E., Elliott R., Youell P., Watson A., Derbyshire S.W., et al. Attention to pain localization and unpleasantness discriminates the functions of the medial and lateral pain systems. The European Journal of Neuroscience 2005, 21(11):3133-3142.
110. Kuo C.C., Chiou R.J., Liang K.C., Yen C.T. Differential involvement of the anterior cingulate and primary sensorimotor cortices in sensory and affective functions of pain. Journal of Neurophysiology 2009, 101(3):1201-1210.
111. Kurrikoff K., Inno J., Matsui T., Vasar E. Stress-induced analgesia in mice: Evidence for interaction between endocannabinoids and cholecystokinin. The European Journal of Neuroscience 2008, 27(8):2147-2155.
112. Kwilasz A.J., Abdullah R.A., Poklis J.L., Lichtman A.H., Negus S.S. Effects of the fatty acid amide hydrolase inhibitor URB597 on pain-stimulated and pain-depressed behavior in rats. Behavioural Pharmacology 2014, 25(2):119-129.
113. La Porta C., Bura A.S., Llorente-Onaindia J., Pastor A., Navarrete F., Garcia-Gutierrez M.S., et al. Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain. Pain 2015, 156(10):2001-2012.
114. LaBuda C.J., Fuchs P.N. Attenuation of negative pain affect produced by unilateral spinal nerve injury in the rat following anterior cingulate cortex activation. Neuroscience 2005, 136(1):311-322.
115. Lafourcade M., Elezgarai I., Mato S., Bakiri Y., Grandes P., Manzoni O.J. Molecular components and functions of the endocannabinoid system in mouse prefrontal cortex. PLoS One 2007, 2(8).
116. Lau B.K., Vaughan C.W. Descending modulation of pain: The GABA disinhibition hypothesis of analgesia. Current Opinion in Neurobiology 2014, 29:159-164.
117. LeDoux J.E. Emotion circuits in the brain. Annual Review of Neuroscience 2000, 23:155-184.
118. Lee M.C., Ploner M., Wiech K., Bingel U., Wanigasekera V., Brooks J., et al. Amygdala activity contributes to the dissociative effect of cannabis on pain perception. Pain 2013, 154(1):124-134.
119. Liao H.T., Lee H.J., Ho Y.C., Chiou L.C. Capsaicin in the periaqueductal gray induces analgesia via metabotropic glutamate receptor-mediated endocannabinoid retrograde disinhibition. British Journal of Pharmacology 2011, 163(2):330-345.
120. Lichtman A.H., Blankman J.L., Cravatt B.F. Endocannabinoid overload. Molecular Pharmacology 2010, 78(6):993-995.
121. Lichtman A.H., Cook S.A., Martin B.R. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: Evidence supporting periaqueductal gray involvement. The Journal of Pharmacology and Experimental Therapeutics 1996, 276(2):585-593.
122. Lichtman A.H., Leung D., Shelton C.C., Saghatelian A., Hardouin C., Boger D.L., et al. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: Evidence for an unprecedented combination of potency and selectivity. The Journal of Pharmacology and Experimental Therapeutics 2004, 311(2):441-448.
123. Lichtman A.H., Martin B.R. Cannabinoid-induced antinociception is mediated by a spinal alpha 2-noradrenergic mechanism. Brain Research 1991, 559(2):309-314.
124. Lichtman A.H., Martin B.R. The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats. Pharmacology Biochemistry and Behavior 1997, 57(1-2):7-12.
125. Lichtman A.H., Shelton C.C., Advani T., Cravatt B.F. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 2004, 109(3):319-327.
126. Little J.P., Carter A.G. Synaptic mechanisms underlying strong reciprocal connectivity between the medial prefrontal cortex and basolateral amygdala. The Journal of Neuroscience 2013, 33(39):15333-15342.
127. Lomazzo E., Bindila L., Remmers F., Lerner R., Schwitter C., Hoheisel U., et al. Therapeutic potential of inhibitors of endocannabinoid degradation for the treatment of stress-related hyperalgesia in an animal model of chronic pain. Neuropsychopharmacology 2015, 40(2):488-501.
128. Ly H.G., Ceccarini J., Weltens N., Bormans G., Van Laere K., Tack J., et al. Increased cerebral cannabinoid-1 receptor availability is a stable feature of functional dyspepsia: A [F]MK-9470 PET study. Psychotherapy and Psychosomatics 2015, 84(3):149-158.
129. Maccarrone M., Bab I., Biro T., Cabral G.A., Dey S.K., Di Marzo V., et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends in Pharmacological Sciences 2015, 36(5):277-296.
130. Madasu M.K., Roche M., Finn D.P. Supraspinal TRPV1 in pain and psychiatric disorders. Modern Trends in Pharmacopsychiatry 2015, 30:36-50.
131. Mailleux P., Parmentier M., Vanderhaeghen J.J. Distribution of cannabinoid receptor messenger RNA in the human brain: An in situ hybridization histochemistry with oligonucleotides. Neuroscience Letters 1992, 143(1-2):200-204.
132. Maione S., Bisogno T., de Novellis V., Palazzo E., Cristino L., Valenti M., et al. Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. The Journal of Pharmacology and Experimental Therapeutics 2006, 316(3):969-982.
133. Maione S., De Petrocellis L., de Novellis V., Moriello A.S., Petrosino S., Palazzo E., et al. Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. British Journal of Pharmacology 2007, 150(6):766-781.
134. Mallet C., Barriere D.A., Ermund A., Jonsson B.A., Eschalier A., Zygmunt P.M., et al. TRPV1 in brain is involved in acetaminophen-induced antinociception. PLoS One 2010, 5(9):e12748.
135. Manning B.H., Martin W.J., Meng I.D. The rodent amygdala contributes to the production of cannabinoid-induced antinociception. Neuroscience 2003, 120(4):1157-1170.
136. Manning B.H., Merin N.M., Meng I.D., Amaral D.G. Reduction in opioid- and cannabinoid-induced antinociception in rhesus monkeys after bilateral lesions of the amygdaloid complex. The Journal of Neuroscience 2001, 21(20):8238-8246.
137. Manzanares J., Corchero J., Fuentes J.A. Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats. Brain Research 1999, 839(1):173-179.
138. Marchand J.E., Hagino N. Afferents to the periaqueductal gray in the rat. A horseradish peroxidase study. Neuroscience 1983, 9(1):95-106.
139. Marsicano G., Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. The European Journal of Neuroscience 1999, 11(12):4213-4225.
140. Martin W.J., Coffin P.O., Attias E., Balinsky M., Tsou K., Walker J.M. Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Research 1999, 822(1-2):237-242.
141. Martin W.J., Hohmann A.G., Walker J.M. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: Correlation between electrophysiological and antinociceptive effects. The Journal of Neuroscience 1996, 16(20):6601-6611.
142. Martin W.J., Lai N.K., Patrick S.L., Tsou K., Walker J.M. Antinociceptive actions of cannabinoids following intraventricular administration in rats. Brain Research 1993, 629(2):300-304.
143. Martin W.J., Patrick S.L., Coffin P.O., Tsou K., Walker J.M. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sciences 1995, 56(23-24):2103-2109.
144. Martin W.J., Tsou K., Walker J.M. Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla. Neuroscience Letters 1998, 242(1):33-36.
145. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346(6284):561-564.
146. May A., Kaube H., Buchel C., Eichten C., Rijntjes M., Juptner M., et al. Experimental cranial pain elicited by capsaicin: A PET study. Pain 1998, 74(1):61-66.
147. McCarberg B.H., Billington R. Consequences of neuropathic pain: Quality-of-life issues and associated costs. The American Journal of Managed Care 2006, 12(9 Suppl.):S263-S268.
148. McGaraughty S., Chu K.L., Bitner R.S., Martino B., El Kouhen R., Han P., et al. Capsaicin infused into the PAG affects rat tail flick responses to noxious heat and alters neuronal firing in the RVM. Journal of Neurophysiology 2003, 90(4):2702-2710.
149. Meagher M.W., Arnau R.C., Rhudy J.L. Pain and emotion: Effects of affective picture modulation. Psychosomatic Medicine 2001, 63(1):79-90.
150. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology 1995, 50(1):83-90.
151. Mechoulam R., Gaoni Y. The absolute configuration of delta-1-tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Letters 1967, 12:1109-1111.
152. Meng I.D., Johansen J.P. Antinociception and modulation of rostral ventromedial medulla neuronal activity by local microinfusion of a cannabinoid receptor agonist. Neuroscience 2004, 124(3):685-693.
153. Meng I.D., Manning B.H., Martin W.J., Fields H.L. An analgesia circuit activated by cannabinoids. Nature 1998, 395(6700):381-383.
154. Millan M.J. The induction of pain: An integrative review. Progress in Neurobiology 1999, 57(1):1-164.
155. Mohammadi-Farani A., Sahebgharani M., Sepehrizadeh Z., Jaberi E., Ghazi-Khansari M. Diabetic thermal hyperalgesia: Role of TRPV1 and CB1 receptors of periaqueductal gray. Brain Research 2010, 1328:49-56.
156. Mohammad-Pour Kargar H., Azizi H., Mirnajafi-Zadeh J., Reza Mani A., Semnanian S. Microinjection of orexin-A into the rat locus coeruleus nucleus induces analgesia via cannabinoid type-1 receptors. Brain Research 2015, 1624:424-432.
157. Monhemius R., Azami J., Green D.L., Roberts M.H. CB1 receptor mediated analgesia from the Nucleus Reticularis Gigantocellularis pars alpha is activated in an animal model of neuropathic pain. Brain Research 2001, 908(1):67-74.
158. Morena M., Patel S., Bains J.S., Hill M.N. Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacology 2015, 10.1038/npp.2015.166.
159. Morgenweck J., Abdel-Aleem O.S., McNamara K.C., Donahue R.R., Badr M.Z., Taylor B.K. Activation of peroxisome proliferator-activated receptor gamma in brain inhibits inflammatory pain, dorsal horn expression of Fos, and local edema. Neuropharmacology 2010, 58(2):337-345.
160. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365(6441):61-65.
161. Neal J.W., Pearson R.C., Powell T.P. The ipsilateral cortico-cortical connections of area 7b, PF, in the parietal and temporal lobes of the monkey. Brain Research 1990, 524(1):119-132.
162. Neugebauer V., Galhardo V., Maione S., Mackey S.C. Forebrain pain mechanisms. Brain Research Reviews 2009, 60(1):226-242.
163. Neugebauer V., Li W., Bird G.C., Han J.S. The amygdala and persistent pain. The Neuroscientist 2004, 10(3):221-234.
164. Nozaki C., Markert A., Zimmer A. Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice. European Neuropsychopharmacology 2015, 25(8):1388-1396.
165. O'Mahony S.M., Bulmer D.C., Coelho A.M., Fitzgerald P., Bongiovanni C., Lee K., et al. 5-HT(2B) receptors modulate visceral hypersensitivity in a stress-sensitive animal model of brain-gut axis dysfunction. Neurogastroenterology and Motility 2010, 22(5):573-578. e124.
166. O'Sullivan S.E. Cannabinoids go nuclear: Evidence for activation of peroxisome proliferator-activated receptors. British Journal of Pharmacology 2007, 152(5):576-582.
167. Okine B.N., Rea K., Olango W.M., Price J., Herdman S., Madasu M.K., et al. A role for PPARalpha in the medial prefrontal cortex in formalin-evoked nociceptive responding in rats. British Journal of Pharmacology 2014, 171(6):1462-1471.
168. Olango W.M., Finn D.P. Neurobiology of stress-induced hyperalgesia. Current Topics in Behavioral Neurosciences 2014, 20:251-280.
169. Olango W.M., Roche M., Ford G.K., Harhen B., Finn D.P. The endocannabinoid system in the rat dorsolateral periaqueductal grey mediates fear-conditioned analgesia and controls fear expression in the presence of nociceptive tone. British Journal of Pharmacology 2012, 165(8):2549-2560.
170. Oliveira M.A., Prado W.A. Antinociception induced by stimulating amygdaloid nuclei in rats: Changes produced by systemically administered antagonists. Brazilian Journal of Medical and Biological Research 1998, 31(5):681-690.
171. Onaivi E.S., Ishiguro H., Gong J.P., Patel S., Perchuk A., Meozzi P.A., et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Annals of the New York Academy of Sciences 2006, 1074:514-536.
172. Otrubova K., Ezzili C., Boger D.L. The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH). Bioorganic & Medicinal Chemistry Letters 2011, 21(16):4674-4685.
173. Palazzo E., de Novellis V., Marabese I., Cuomo D., Rossi F., Berrino L., et al. Interaction between vanilloid and glutamate receptors in the central modulation of nociception. European Journal of Pharmacology 2002, 439(1-3):69-75.
174. Palazzo E., Marabese I., de Novellis V., Oliva P., Rossi F., Berrino L., et al. Metabotropic and NMDA glutamate receptors participate in the cannabinoid-induced antinociception. Neuropharmacology 2001, 40(3):319-326.
175. Palazzo E., Rossi F., Maione S. Role of TRPV1 receptors in descending modulation of pain. Molecular and Cellular Endocrinology 2008, 286(1-2 Suppl. 1):S79-S83.
176. Patel S., Cravatt B.F., Hillard C.J. Synergistic interactions between cannabinoids and environmental stress in the activation of the central amygdala. Neuropsychopharmacology 2005, 30(3):497-507.
177. Pertwee R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacology & Therapeutics 1997, 74(2):129-180.
178. Pertwee R.G. Cannabinoid receptors and pain. Progress in Neurobiology 2001, 63(5):569-611.
179. Petrosino S., Palazzo E., de Novellis V., Bisogno T., Rossi F., Maione S., et al. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 2007, 52(2):415-422.
180. Racz I., Nent E., Erxlebe E., Zimmer A. CB1 receptors modulate affective behaviour induced by neuropathic pain. Brain Research Bulletin 2015, 114:42-48.
181. Rademacher D.J., Meier S.E., Shi L., Ho W.S., Jarrahian A., Hillard C.J. Effects of acute and repeated restraint stress on endocannabinoid content in the amygdala, ventral striatum, and medial prefrontal cortex in mice. Neuropharmacology 2008, 54(1):108-116.
182. Raffa R.B., Stone D.J., Hipp S.J. Differential cholera-toxin sensitivity of supraspinal antinociception induced by the cannabinoid agonists delta9-THC, WIN 55,212-2 and anandamide in mice. Neuroscience Letters 1999, 263(1):29-32.
183. Rea K., Olango W.M., Harhen B., Kerr D.M., Galligan R., Fitzgerald S., et al. Evidence for a role of GABAergic and glutamatergic signalling in the basolateral amygdala in endocannabinoid-mediated fear-conditioned analgesia in rats. Pain 2013, 154(4):576-585.
184. Rea K., Olango W.M., Okine B.N., Madasu M.K., McGuire I.C., Coyle K., et al. Impaired endocannabinoid signalling in the rostral ventromedial medulla underpins genotype-dependent hyper-responsivity to noxious stimuli. Pain 2014, 155(1):69-79.
185. Rhudy J.L., Meagher M.W. Fear and anxiety: Divergent effects on human pain thresholds. Pain 2000, 84(1):65-75.
186. Rhudy J.L., Meagher M.W. Noise stress and human pain thresholds: Divergent effects in men and women. The Journal of Pain 2001, 2(1):57-64.
187. Rhudy J.L., Meagher M.W. Individual differences in the emotional reaction to shock determine whether hypoalgesia is observed. Pain Medicine 2003, 4(3):244-256.
188. Rhudy J.L., Meagher M.W. Negative affect: Effects on an evaluative measure of human pain. Pain 2003, 104(3):617-626.
189. Roche M., Johnston P., Mhuircheartaigh O.N., Olango W.M., Mackie K., Finn D.P. Effects of intra-basolateral amygdala administration of rimonabant on nociceptive behaviour and neuronal activity in the presence or absence of contextual fear. European Journal of Pain 2010, 14(5):487-495.
190. Roche M., O'Connor E., Diskin C., Finn D.P. The effect of CB(1) receptor antagonism in the right basolateral amygdala on conditioned fear and associated analgesia in rats. The European Journal of Neuroscience 2007, 26(9):2643-2653.
191. Russo E.B. Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?. Neuro Endocrinology Letters 2004, 25(1-2):31-39.
192. Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R.M., Tanaka H., et al. Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998, 92(5). 1 page following 696.
193. Santos A.R., Calixto J.B. Ruthenium red and capsazepine antinociceptive effect in formalin and capsaicin models of pain in mice. Neuroscience Letters 1997, 235(1-2):73-76.
194. Sierra-Mercado D., Corcoran K.A., Lebron-Milad K., Quirk G.J. Inactivation of the ventromedial prefrontal cortex reduces expression of conditioned fear and impairs subsequent recall of extinction. The European Journal of Neuroscience 2006, 24(6):1751-1758.
195. Sim-Selley L.J., Vogt L.J., Vogt B.A., Childers S.R. Cellular localization of cannabinoid receptors and activated G-proteins in rat anterior cingulate cortex. Life Sciences 2002, 71(19):2217-2226.
196. Smith S.C., Wagner M.S. Clinical endocannabinoid deficiency (CECD) revisited: Can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?. Neuro Endocrinology Letters 2014, 35(3):198-201.
197. Starowicz K., Nigam S., Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacology & Therapeutics 2007, 114(1):13-33.
198. Staton P.C., Hatcher J.P., Walker D.J., Morrison A.D., Shapland E.M., Hughes J.P., et al. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 2008, 139(1):225-236.
199. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., et al. 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochemical and Biophysical Research Communications 1995, 215(1):89-97.
200. Suplita R.L., Farthing J.N., Gutierrez T., Hohmann A.G. Inhibition of fatty-acid amide hydrolase enhances cannabinoid stress-induced analgesia: Sites of action in the dorsolateral periaqueductal gray and rostral ventromedial medulla. Neuropharmacology 2005, 49(8):1201-1209.
201. Svensson P., Minoshima S., Beydoun A., Morrow T.J., Casey K.L. Cerebral processing of acute skin and muscle pain in humans. Journal of Neurophysiology 1997, 78(1):450-460.
202. Szabo B., Schlicker E. Effects of cannabinoids on neurotransmission. Handbook of Experimental Pharmacology 2005, 168:327-365.
203. Task Force on Taxonomy of the International Association for the Study of Pain. (1994). Classification of chronic pain: Descriptions of chronic pain syndromes and definitions of pain terms. (2nd ed.). Seattle: IASP Press (Part 3).
204. Taylor B.K., Kriedt C., Nagalingam S., Dadia N., Badr M. Central administration of perfluorooctanoic acid inhibits cutaneous inflammation. Inflammation Research 2005, 54(6):235-242.
205. Thomas B.F., Wei X., Martin B.R. Characterization and autoradiographic localization of the cannabinoid binding site in rat brain using [3H]11-OH-delta 9-THC-DMH. The Journal of Pharmacology and Experimental Therapeutics 1992, 263(3):1383-1390.
206. Toms L., McQuay H.J., Derry S., Moore R.A. Single dose oral paracetamol (acetaminophen) for postoperative pain in adults. Cochrane Database of Systematic Reviews 2008, 4. CD004602.
207. Treede R.D., Kenshalo D.R., Gracely R.H., Jones A.K. The cortical representation of pain. Pain 1999, 79(2-3):105-111.
208. Tsou K., Brown S., Sanudo-Pena M.C., Mackie K., Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998, 83(2):393-411.
209. Tsou K., Nogueron M.I., Muthian S., Sanudo-Pena M.C., Hillard C.J., Deutsch D.G., et al. Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry. Neuroscience Letters 1998, 254(3):137-140.
210. Tsujino N., Sakurai T. Orexin/hypocretin: A neuropeptide at the interface of sleep, energy homeostasis, and reward system. Pharmacological Reviews 2009, 61(2):162-176.
211. Turk D.C. Clinical effectiveness and cost-effectiveness of treatments for patients with chronic pain. The Clinical Journal of Pain 2002, 18(6):355-365.
212. Ueda N., Tsuboi K., Uyama T., Ohnishi T. Biosynthesis and degradation of the endocannabinoid 2-arachidonoylglycerol. Biofactors 2011, 37(1):1-7.
213. Valverde O., Ledent C., Beslot F., Parmentier M., Roques B.P. Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors. The European Journal of Neuroscience 2000, 12(2):533-539.
214. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310(5746):329-332.
215. Vanegas H., Barbaro N.M., Fields H.L. Tail-flick related activity in medullospinal neurons. Brain Research 1984, 321(1):135-141.
216. Vaughan C.W., Connor M., Bagley E.E., Christie M.J. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Molecular Pharmacology 2000, 57(2):288-295.
217. Vazquez E., Escobar W., Ramirez K., Vanegas H. A nonopioid analgesic acts upon the PAG-RVM axis to reverse inflammatory hyperalgesia. The European Journal of Neuroscience 2007, 25(2):471-479.
218. Vos T., Flaxman A.D., Naghavi M., Lozano R., Michaud C., Ezzati M., et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380(9859):2163-2196.
219. Walker J.M., Hohmann A.G. Cannabinoid mechanisms of pain suppression. Handbook of Experimental Pharmacology 2005, 168:509-554.
220. Walker J.M., Huang S.M., Strangman N.M., Tsou K., Sanudo-Pena M.C. Pain modulation by release of the endogenous cannabinoid anandamide. Proceedings of the National Academy of Sciences of the United States of America 1999, 96(21):12198-12203.
221. Wedzony K., Chocyk A. Cannabinoid CB1 receptors in rat medial prefrontal cortex are colocalized with calbindin- but not parvalbumin- and calretinin-positive GABA-ergic neurons. Pharmacological Reports 2009, 61(6):1000-1007.
222. Welch S.P., Huffman J.W., Lowe J. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. The Journal of Pharmacology and Experimental Therapeutics 1998, 286(3):1301-1308.
223. Welch S.P., Thomas C., Patrick G.S. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: Possible mechanisms for interaction with morphine. The Journal of Pharmacology and Experimental Therapeutics 1995, 272(1):310-321.
224. Werka T. Post-stress analgesia in rats with partial amygdala lesions. Acta Neurobiologiae Experimentalis (Wars) 1994, 54(2):127-132.
225. Werka T. The effects of the medial and cortical amygdala lesions on post-stress analgesia in rats. Behavioural Brain Research 1997, 86(1):59-65.
226. Werka T., Marek P. Post-stress analgesia after lesions to the central nucleus of the amygdala in rats. Acta Neurobiologiae Experimentalis (Wars) 1990, 50(1-2):13-22.
227. Wiech K., Tracey I. The influence of negative emotions on pain: Behavioral effects and neural mechanisms. NeuroImage 2009, 47(3):987-994.
228. Wilson A.R., Maher L., Morgan M.M. Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociception. Neuropharmacology 2008, 55(7):1219-1225.
229. Wilson-Poe A.R., Pocius E., Herschbach M., Morgan M.M. The periaqueductal gray contributes to bidirectional enhancement of antinociception between morphine and cannabinoids. Pharmacology Biochemistry and Behavior 2013, 103(3):444-449.
230. Woodhams S.G., Sagar D.R., Burston J.J., Chapman V. The role of the endocannabinoid system in pain. Handbook of Experimental Pharmacology 2015, 227:119-143.
231. Yamamoto T., Yamamoto A., Watanabe M., Matsuo T., Yamazaki N., Kataoka M., et al. Classification of FABP isoforms and tissues based on quantitative evaluation of transcript levels of these isoforms in various rat tissues. Biotechnology Letters 2009, 31(11):1695-1701.
232. Zhang H.Y., Gao M., Liu Q.R., Bi G.H., Li X., Yang H.J., et al. Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proceedings of the National Academy of Sciences of the United States of America 2014, 111(46):E5007-E5015.
233. Zygmunt P.M., Chuang H., Movahed P., Julius D., Hogestatt E.D. The anandamide transport inhibitor AM404 activates vanilloid receptors. European Journal of Pharmacology 2000, 396(1):39-42.